3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
Ming Yu seeks a share of the drug sector limelight
Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO Key Takeaways:…
CSPC feels the pain from sweeping cuts in drug prices
The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…
BRIEF: Surging drug sales drive Hengrui Pharma’s profit growth
Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) saidon Wednesday that its revenue for the first half of 2025 reached 15.76 billion yuan ($2.19 billion), up 15.9% year-on-year. Its…
CSPC Pharma teases big bucks deals after earnings miss
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster…
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
Shares of Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) jumped in their Hong Kong trading debut on Friday, as the leading drug maker’s new IPO complemented its existing listing in…
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
Despite already having three products on the market, unlike many of its Hong Kong-listed peers, the drug maker is struggling to cover its daily operational costs Key Takeaways: Mabwell said…
Recent Articles
BRIEF: Surging drug sales drive Hengrui Pharma’s profit growth
1276.HK
600276.SHG
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
1276.HK
600276.SHG
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK688331.SHG
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
-
Zai Lab under pressure over clinical results and rival drugs
9688.HKZLAB.US
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
-
Akeso shares take a hit despite surging sales of cancer drugs
9926.HK
-
BRIEF: Ubtech to raise $400 million in share placement at 11.4% discount
9880.HK
